Physician

Daniel P Anderson, MD

According to 2025 Medicare claims, Daniel Anderson, MD (NPI: 1356320675) practices family practice in the Mankato, MN market, with the plurality of this provider's patient population coming from Blue Earth, MN. This provider's primary affiliated billing organization is MANKATO CLINIC LTD (NPI: 1629044029; TIN: 410849339) and primary practice location at 56003-2503. Anderson is affiliated with the Stratum Med ACO (ACO ID: A4527), Mayo Clinic Community ACO, LLC (ACO ID: A4617), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Anderson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 446 traditional Medicare patients, billed 8,787 HCPCS/CPT codes, and received $202,697 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 8,414 prescription claims across 656 beneficiaries totaling $612,509 in drug costs, led by Trulicity (Dulaglutide). DME data shows 132 claims. Open Payments data shows 3 records totaling $49. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $99,331 to $202,697. Concurrently, Part D prescription costs have changed little. For DME billing, reported payments moved sharply higher in recent years, from $27,041 to $51,845.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	345	4,052	$99,331
2016	308	3,636	$88,577
2017	297	5,867	$90,796
2018	294	2,869	$83,764
2019	552	9,103	$182,661
2020	507	6,592	$147,897
2021	508	10,297	$182,152
2022	484	10,057	$169,021
2023	452	8,215	$193,027
2024	446	8,787	$202,697

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	605	8,889	$606,767
2016	689	9,358	$694,475
2017	692	8,707	$624,366
2018	643	7,957	$501,094
2019	624	8,161	$521,578
2020	639	8,389	$552,846
2021	641	8,344	$598,868
2022	654	8,714	$728,927
2023	642	8,231	$786,889
2024	656	8,414	$612,509

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	65	254	$23,867
2016	60	213	$5,764
2017	43	219	$4,837
2018	44	182	$4,461
2019	54	178	$7,273
2020	52	262	$13,083
2021	39	279	$13,919
2022	42	201	$11,986
2023	37	183	$19,989
2024	39	132	$25,637

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	295	295	$126
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	298	422	$84
80061	Blood test, lipids (cholesterol and triglycerides)	243	262	$13
36415	Insertion of needle into vein for collection of blood sample	335	547	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	215	226	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trulicity	Dulaglutide	46	2,940	$94,599
Eliquis	Apixaban	61	3,837	$70,511
Xarelto	Rivaroxaban	53	3,930	$69,911
Ozempic	Semaglutide	31	1,540	$48,251
Jardiance	Empagliflozin	19	1,710	$33,429

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	12	53	$24,006
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	14	$965
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	16	43	$632
A4259	Lancets, per box of 100	N	11	22	$33

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$49	Xeris Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel P. Anderson, MD?

Tedicare shows public-source Medicare data for Daniel P. Anderson, MD (NPI 1356320675), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel P. Anderson, MD have ACO affiliation data?

Daniel P. Anderson, MD is shown with ACO affiliation data for Stratum Med ACO (MSSP, ACO ID A4527), Mayo Clinic Community ACO, LLC (MSSP, ACO ID A4617), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Daniel P. Anderson, MD?

Daniel P. Anderson, MD is linked to MANKATO CLINIC LTD (billing NPI 1629044029) in the available physician profile data.

Does Daniel P. Anderson, MD have Open Payments data?

Daniel P. Anderson, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.